- Immune checkpoint inhibitor use is common in oncology care
- A rare paradoxical rapid progression in tumor growth after initiation of immunotherapy (Figure 1) has been described and termed Hyperprogressive disease (HPD)
- Frequency of HPD has been reported from 6% to 29%, with highest frequency in HNSCC and NSCLC
- EGFR mutations and MDM2/4 amplifications have been implicated in HPD, but underlying molecular mechanism remains unclear necessitating further study
Publications
Genetic and molecular analysis of solid tumors with immunotherapy associated hyperprogressive disease
– Caris Life Sciences